A 26-week, Randomized, Open-label, 3-arm Parallel, Treat-to-target Study Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin With or Without One Other Oral Anti-diabetic Drug
Latest Information Update: 04 Apr 2024
At a glance
- Drugs HR 17031 (Primary) ; HS 20004; Insulin degludec
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 04 Apr 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified April 2022).
- 23 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 25 Jul 2022 Status changed from not yet recruiting to recruiting.